7 unchanged sentences
and AstraZeneca AB, dated as of October 20, 2014.
−Removed: Amended and Restated Equity Distribution Agreement by and between FibroGen, Inc.
−Removed: and Goldman Sachs & Co.
−Removed: LLC and BofA Securities, Inc., dated February 27, 2023.
Amendment No.
1 unchanged sentence
and its Affiliates and Catalent Pharma Solutions, LLC dated as of January 1, 2023.
−Removed: FibroGen, Inc.
−Removed: Non-Employee Director Compensation Policy, as amended.
−Removed: Form of Executive Officer Change in Control and Severance Agreement.
+Added: Offer Letter, dated July 23, 2023, between FibroGen, Inc.
+Added: and Thane Wettig.
+Added: Consulting Agreement, dated July 23, 2023, between FibroGen, Inc.
+Added: and Enrique Conterno.
+Added: Amended and Restated Exclusive License Agreement by and among FibroGen, Inc., FibroGen (China) Medical Technology Development Co., Ltd., and Eluminex Biosciences Suzhou) Limited, dated April 19, 2023.
+Added: Financing Agreement by and among FibroGen, Inc., certain of its subsidiaries, NHTV Fairview Holding LLC, NHTV II Fairview Holding LLC, MSTV Fund II Employees Fairview Holding LLC, and Wilmington Trust, National Association, dated as of April 29, 2023.
+Added: Evaluation Agreement by and between FibroGen, Inc.
+Added: and Fortis Therapeutics, Inc., dated May 5, 2023.
+Added: Option Agreement and Plan of Merger by and among FibroGen, Inc., Fortis Therapeutics, Inc., and Shareholder Representative Services LLC, dated as of May 5, 2023.
Certification of Chief Executive Officer, as required by Rule 13a-14(a) or Rule 15d-14(a).
9 unchanged sentences
Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101.)
−Removed: * Filed herewith
Portions of this exhibit (indicated by asterisks) have been omitted as the Company has determined that (i) the omitted information is not material and (ii) the omitted information would likely cause competitive harm if publicly disclosed or is the type of information the Company treats as confidential.
+ Indicates a management contract or compensatory plan.
+Added: * Filed herewith
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
FibroGen, Inc.
−Removed: /s/ Enrique Conterno
−Removed: Enrique Conterno
−Removed: Chief Executive Officer
+Added: August 7, 2023
+Added: /s/ Thane Wettig
+Added: Interim Chief Executive Officer
(Principal Executive Officer)
+Added: August 7, 2023
/s/ Juan Graham
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.